{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T12:12:49Z","timestamp":1794399169698,"version":"4.9.0"},"reference-count":35,"publisher":"BMJ","issue":"8","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2024,12,4]]},"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Data regarding long-term recovery from autoimmune encephalitis (AE) remain limited.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective observational study investigated outcomes in 182 patients who met the 2016 criteria for definite AE. Recovery data were available in 172 patients. Follow-up data at \u226524 months post-attack were available for 119. Recovery trajectory, residual symptoms, outcome predictors and causes of post-AE death were assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 172 patients, 138 (80%) achieved good recovery (modified Rankin Scale (mRS) \u22642) with a median recovery time of 4 months (95% CI: 2 to 6 months). Recovery varied by associated neural antibody, with the best recovery observed in leucine-rich glioma-inactivated 1 (97% good recovery, median recovery time 0 (0 to 2) months). Paraneoplastic AE (p=0.007), severe attacks (eg, mRS \u22654 at attack, p=0.007) and cerebrospinal fluid pleocytosis (p=0.005) were associated with a lower likelihood of good recovery, while seizure presentation (p=0.026) was associated with better recovery. Despite good recovery, several residual symptoms persisted \u226524 months post-AE, including cognitive deficits (53%), seizures (26%), depression (23%), sleep disorders (25%), brainstem\/cerebellar symptoms (13%), other movement disorders (14%) and autonomic symptoms (12%). Predictors of long-term sequelae included disabling cognitive deficit at onset and delayed immunotherapy for post AE-dementia, and medial temporal atrophy as well as escalation to cyclophosphamide therapy for both drug-resistant epilepsy and chronic depression. Of 182 patients, 20 (11%) died; the most common cause of death was progression of AE (6\/20 (30%)).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>While the majority of patients achieved functional independence after AE, several residual symptoms persisted. Several clinical and paraclinical features were associated with long-term sequelae.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jnnp-2024-334957","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T01:16:25Z","timestamp":1737335785000},"page":"736-743","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":16,"title":["Autoimmune encephalitis: recovery, residual symptoms and predictors of long-term sequelae"],"prefix":"10.1136","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0607-904X","authenticated-orcid":false,"given":"Smathorn","family":"Thakolwiboon","sequence":"first","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"Department of Neurology, Mayo Clinic Health System, La Crosse, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gilligan","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Orozco","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W","family":"Britton","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divyanshu","family":"Dubey","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6661-2910","authenticated-orcid":false,"given":"Eoin P","family":"Flanagan","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A Sebastian","family":"Lopez-Chiriboga","sequence":"additional","affiliation":[{"name":"Neurology, Mayo Clinic, Jacksonville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0116-8035","authenticated-orcid":false,"given":"Cristina","family":"Valencia-Sanchez","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas L","family":"Zalewski","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1960-9065","authenticated-orcid":false,"given":"Anastasia","family":"Zekeridou","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6140-5584","authenticated-orcid":false,"given":"Sean J","family":"Pittock","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6856-8143","authenticated-orcid":false,"given":"Andrew","family":"McKeon","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA"},{"name":"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,1,19]]},"reference":[{"key":"2025071606150574000_96.8.736.1","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/hvaa254"},{"key":"2025071606150574000_96.8.736.2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25131"},{"key":"2025071606150574000_96.8.736.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00401-9"},{"key":"2025071606150574000_96.8.736.4","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-325300"},{"key":"2025071606150574000_96.8.736.5","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh203"},{"key":"2025071606150574000_96.8.736.6","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70310-1"},{"key":"2025071606150574000_96.8.736.7","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-325275"},{"key":"2025071606150574000_96.8.736.8","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2021-327302"},{"key":"2025071606150574000_96.8.736.9","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(07)61602-x"},{"key":"2025071606150574000_96.8.736.10","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200151","article-title":"Autoimmune Encephalitis Criteria in Clinical Practice","volume":"13","author":"Orozco","year":"2023","journal-title":"Neurol Clin Pract"},{"key":"2025071606150574000_96.8.736.11","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001014","article-title":"Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes","volume":"8","author":"Graus","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025071606150574000_96.8.736.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-6196(12)61905-3"},{"key":"2025071606150574000_96.8.736.13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2005.53221.x"},{"key":"2025071606150574000_96.8.736.14","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"2025071606150574000_96.8.736.15","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25421"},{"key":"2025071606150574000_96.8.736.16","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13670"},{"key":"2025071606150574000_96.8.736.17","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders. 5th edn. Arlington, VA: American Psychiatric Publishing, 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"2025071606150574000_96.8.736.18","unstructured":"World Health Organization . International Classification of Diseases 11th Revision (ICD-11). Geneva: World Health Organization, 2019."},{"key":"2025071606150574000_96.8.736.19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02397.x"},{"key":"2025071606150574000_96.8.736.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.120124"},{"key":"2025071606150574000_96.8.736.21","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.642078","article-title":"Characteristics and Prognosis of Autoimmune Encephalitis in the East of China: A Multi-Center Study","volume":"12","author":"Qiao","year":"2021","journal-title":"Front Neurol"},{"key":"2025071606150574000_96.8.736.22","doi-asserted-by":"publisher","DOI":"10.1177\/003693305700200504"},{"key":"2025071606150574000_96.8.736.23","doi-asserted-by":"publisher","DOI":"10.1017\/cjn.2018.33"},{"key":"2025071606150574000_96.8.736.24","first-page":"e1141","article-title":"Clinical Course and Features of Seizures Associated With LGI1-Antibody Encephalitis","volume":"97","author":"Smith","year":"2021","journal-title":"Neurology (ECronicon)"},{"key":"2025071606150574000_96.8.736.25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2019.07.049"},{"key":"2025071606150574000_96.8.736.26","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30244-3"},{"key":"2025071606150574000_96.8.736.27","doi-asserted-by":"crossref","unstructured":"Guo K , Liu X , Lin J , et al . Clinical characteristics, long-term functional outcomes and relapse of anti-LGI1\/Caspr2 encephalitis: a prospective cohort study in Western China. Ther Adv Neurol Disord 2022;15. doi:10.1177\/17562864211073203","DOI":"10.1177\/17562864211073203"},{"key":"2025071606150574000_96.8.736.28","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000958","article-title":"Long-term Functional Outcomes and Relapse of Anti-NMDA Receptor Encephalitis: A Cohort Study in Western China","volume":"8","author":"Gong","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025071606150574000_96.8.736.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2017.04.046"},{"key":"2025071606150574000_96.8.736.30","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2010.0326"},{"key":"2025071606150574000_96.8.736.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2019.10.020"},{"key":"2025071606150574000_96.8.736.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2023.107854"},{"key":"2025071606150574000_96.8.736.33","doi-asserted-by":"publisher","DOI":"10.1177\/0891988714541873"},{"key":"2025071606150574000_96.8.736.34","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.845365","article-title":"Risk Factors for Mortality in Anti-NMDAR, Anti-LGI1, and Anti-GABABR Encephalitis","volume":"13","author":"Zhong","year":"2022","journal-title":"Front Immunol"},{"key":"2025071606150574000_96.8.736.35","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000003173"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2024-334957","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T13:15:34Z","timestamp":1752671734000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2024-334957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,19]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,7,16]]},"published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1136\/jnnp-2024-334957"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2024-334957","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,19]]}}}